FILTER
FILTERED INTERVIEW RESULTS
Dr. Mark Bristow
CEO, RANDGOLD RESOURCES
Rangold speaks to GBR about its mining operations across Africa with a focus on the DRC.
Oumarou Idani
MINISTER OF MINES AND QUARRIES, MINISTRY OF MINES, QUARRIES AND ENERGY, BURKINA FASO
GBR speaks to The Minister of Mines in Burkina Faso about the country’s fast expanding mining sector that is mostly focused on gold.
Michael Demey
REGIONAL MANAGER FOR THE SOUTH, BCDC
GBR speaks to BCDC bank in Katanga, DRC, about the role of local Congolese banks in international mining investments.
Bill Witham
CEO, AAMEG
AAMEG endeavors to provide Australian companies operating in Africa with a platform to network and discuss critical issues facing the industry today.
John Gladston
GOVERNMENT AFFAIRS MANAGER, FIRST QUANTUM MINERALS (FQM)
FQM explains to GBR the operational challenges in Zambia where the company plays a crucial economic role.
Francois Godin
CEO, GRANDE CÔTE OPERATIONS
GCO speaks to GBR about its mineral sands operation in Senegal.
Mouhamed Kebe, Mohamed Abdallah Dieng & Ismael Itoua
MANAGING PARTNER, ATTORNEY & COUNSEL, GENI & KÉBÉ
GBR speaks to Geni & Kébé about how the law firm can serve investors in West African mining.
John Kanyoni
COO DRC, TEMBO POWER
Tembo Power explains its plans to develop hydropower in the DRC that will supply the growing demand from the countries mines.
Richard Young
PRESIDENT & CEO, TERANGA GOLD
With a producing gold mine in Senegal, Teranga’s exploration focus for 2018 is on Burkina Faso and Cote d’Ivoire.
Mbiya Ngandu
DIRECTOR, TRUST MERCHANT BANK (TMB)
GBR talks to TMB, a leading corporate and commercial bank in DRC, about what is attracting investments to the country and the services that the bank can offer.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
